Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EPS (Weighted Average and Diluted) (2020 - 2025)

Historic EPS (Weighted Average and Diluted) for Cytek Biosciences (CTKB) over the last 5 years, with Q3 2025 value amounting to -$0.04.

  • Cytek Biosciences' EPS (Weighted Average and Diluted) fell 50000.0% to -$0.04 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.1, marking a year-over-year decrease of 2500.0%. This contributed to the annual value of -$0.05 for FY2024, which is 4878.78% up from last year.
  • As of Q3 2025, Cytek Biosciences' EPS (Weighted Average and Diluted) stood at -$0.04, which was down 50000.0% from -$0.04 recorded in Q2 2025.
  • Cytek Biosciences' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.07 during Q4 2024, with a 5-year trough of -$0.09 in Q1 2025.
  • For the 4-year period, Cytek Biosciences' EPS (Weighted Average and Diluted) averaged around -$0.02, with its median value being -$0.04 (2025).
  • In the last 5 years, Cytek Biosciences' EPS (Weighted Average and Diluted) plummeted by 60000.0% in 2023 and then skyrocketed by 12000.0% in 2024.
  • Cytek Biosciences' EPS (Weighted Average and Diluted) (Quarter) stood at $0.03 in 2022, then skyrocketed by 33.33% to $0.04 in 2023, then soared by 84.57% to $0.07 in 2024, then tumbled by 154.18% to -$0.04 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.04 for Q3 2025, versus -$0.04 for Q2 2025 and -$0.09 for Q1 2025.